# Stanford Scientists Use AI to Identify Potential Natural Weight Loss Molecule A newly discovered peptide, BRP, shows promise in suppressing appetite without common side effects. - **Source:** [ScienceDaily – Top](https://www.sciencedaily.com) - **Published:** 2026-11-04 - **Topic:** [health](https://brifing.si/c/health) - **Original article:** - **On Brifing:** https://brifing.si/s/8a3eb135-2132-4987-88a1-1bf2fd3c35c4 ## AI-Driven Discovery Process Stanford researchers utilized an AI algorithm named Peptide Predictor to analyze 20,000 human genes. By focusing on specific enzyme cutting sites, they narrowed down thousands of potential candidates to 373 prohormones. This computational approach significantly accelerated the identification of BRP, a novel peptide that shows potential for regulating human appetite and metabolism. ## Targeting the Hypothalamus Unlike semaglutide, which affects receptors throughout the gut and pancreas, BRP appears to act selectively within the hypothalamus. This brain region is critical for controlling hunger and energy balance. By focusing on this specific area, researchers hope to achieve weight loss while minimizing systemic side effects like nausea and constipation. ## Potent Neuronal Activation In laboratory tests using nerve cells, BRP demonstrated a powerful response. The 12-amino-acid peptide increased neuronal activity tenfold compared to control cells. This performance significantly outperformed GLP-1, which increased activity by three times. Such results suggest that BRP could be a highly effective signaling molecule for appetite suppression in humans. ## Animal Study Results Experiments on lean mice and minipigs showed that BRP injections reduced food intake by up to 50% within an hour. In obese mice, a 14-day treatment regimen resulted in significant fat loss. Crucially, the animals maintained muscle mass, a vital factor for preserving metabolic health and physical mobility during weight reduction. ## Side Effect Profile Researchers closely monitored treated animals for adverse reactions commonly associated with existing weight loss drugs. They observed no significant changes in fecal output, anxiety-related behavior, or water consumption. The absence of digestive distress in these animal models provides an early, optimistic indicator that BRP might offer a more tolerable treatment option. ## Mechanism of Action BRP functions by activating distinct neuronal pathways rather than simply mimicking GLP-1 hormones. By targeting specific brain cells, it influences metabolic functions without triggering the widespread physiological effects seen with current medications. This unique pathway is the primary reason scientists believe it could avoid the common side effects of existing therapies. ## Path to Clinical Trials Assistant professor Katrin Svensson and senior researcher Laetitia Coassolo are leading the effort to advance BRP toward human clinical trials. They have cofounded a company to facilitate this transition. The team must now determine the molecule's safety and effectiveness in humans, alongside identifying the specific cell surface receptors that BRP activates. ## Future Development Challenges Despite promising results, BRP remains in early development. Scientists need to understand how the molecule communicates with cells and how to extend its activity duration within the body. Because peptides are often broken down quickly, developing a longer-lasting version will be essential for creating a convenient and practical treatment for patients. ## Significance of the Breakthrough Obesity remains a persistent global health challenge with limited effective pharmaceutical interventions. While semaglutide has set a high standard for weight loss, the potential for a more targeted, side-effect-free alternative is significant. If human trials confirm these animal findings, BRP could represent a major advancement in the medical management of metabolic disorders. ## Sources covering this story - https://www.sciencedaily.com/releases/2026/11/261104004909.htm — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._